■在ETNA-AF(常规临床实践中的依多沙班治疗)研究中,分析了房颤(AF)患者的依多沙班治疗的实际结果,该研究涉及来自多个区域注册中心的数据。本报告讨论了edoxaban在韩国ETNA-AF人群中的有效性和安全性。
■根据edoxaban剂量和患者年龄对来自1887名韩国ETNA-AF参与者的一年数据进行分析,并与其他ETNA-AF注册的结果进行比较。
■大约70%的患者接受了推荐剂量的依度沙班(60mg/30mg);非推荐的60mg和30mg剂量分别用于9.6%和19.8%的患者,分别。参考年龄(<65岁)的比例,最年轻(65-74岁)和中年/最年长(≥75岁)组占21.4%,40.2%,和38.4%,分别。在剂量组(0.57%-1.71%)和年龄亚组(1.26%-1.63%)内,主要或临床相关的非主要出血的发生率相似。净临床结果的发生率,一个合成的行程,全身栓塞事件,大出血,和全因死亡率,在剂量亚组(1.14%-3.10%)和年龄亚组(2.28%-2.78%)之间也具有可比性。接受非推荐30mg的韩国患者的百分比(19.8%)是欧洲人群(8.4%)的两倍以上。然而,ETNA-AF研究中不同人群的临床结局大致相似.
■韩国ETNA-AF人群的结果与全球ETNA-AF人群的结果相似,卒中事件的总体发生率较低,不同年龄和剂量亚组的大出血和全因死亡率。依多沙班可有效安全地用于韩国房颤患者的特定人群,包括老人。
UNASSIGNED: The real-world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA-AF (Edoxaban Treatment in Routine Clinical Practice)
study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA-AF population.
UNASSIGNED: One-year data from 1887 Korean ETNA-AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA-AF registries.
UNASSIGNED: Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non-recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (<65 years), youngest-old (65-74 years) and middle-old/oldest-old (≥75 years) groups were 21.4%, 40.2%, and 38.4%, respectively. Incidence of major or clinically relevant nonmajor bleeding was similar within dose (0.57%-1.71%) and age subgroups (1.26%-1.63%). Incidence of net clinical outcome, a composite of stroke, systemic embolic event, major bleeding, and all-cause mortality, was also comparable among dose subgroups (1.14%-3.10%) and age subgroups (2.28%-2.78%). The percentage of Korean patients receiving non-recommended 30 mg (19.8%) was over twice that of the European population (8.4%). However, the clinical outcomes were generally similar among different populations included in the ETNA-AF
study.
UNASSIGNED: The outcomes in the Korean ETNA-AF population are like those in the global ETNA-AF population, with overall low event rates of stroke, major bleeding and all-cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly.